Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 10/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420745 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PIK3CDDDB1 | |
| SCHEMBL2349633 | 0.87 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL17499881 | 0.87 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2PIK3CDRORC | |
| SCHEMBL16414857 | 0.86 | HPGD (0.43) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL18280935 | 0.86 | HPGD (0.43) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL18281007 | 0.86 | HPGD (0.43) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL28573624 | 0.85 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PIK3CDRORC | |
| SCHEMBL25339655 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2PIK3CDDDB1 | |
| SCHEMBL25956594 | 0.82 | MEN1 (0.44) | NR1H2USP2SMN1; SMN2PIK3CDRORC | |
| SCHEMBL15719645 | 0.80 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PIK3CDDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-112654620-B | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3847173-B1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3847173-A1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| CN-112654620-A | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2970262-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | KCNJ1, KCNJ11, SSB | NR1H2 1481/4885USP2 4777/4885SMN1; SMN2 1949/4885 |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | KCNJ1, KCNJ11, SSB | NR1H2 1481/4885USP2 4777/4885SMN1; SMN2 1949/4885 |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | NR1H2 955/4885USP2 1523/4885SMN1; SMN2 2785/4885 |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | NR1H2 3108/4885USP2 3771/4885SMN1; SMN2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.